Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Antiviral Res. 2013 Mar 21;98(2):135–143. doi: 10.1016/j.antiviral.2013.03.009

Figure 5. Effect of post-exposure vaccination with MP-12 or MP-12 lacking NSs on survival outcome in mice challenged s.c. with wt RVFV.

Figure 5

Mice in each group (n=10) were challenged with 102.5 PFU of RVFV, then treated s.c. with 105 PFU of MP-12, rMP12-C13type or rMP12-mPKRN167 at 30 minutes post-infection. ***P < 0.001 compared to animals receiving placebo (n=20), bP < 0.01 compared to animals receiving MP-12.